Evidence map›Paper›PMID 41348662›Full record

ReviewOncology2026

Business Intelligence in Radiation Oncology: About Potential and Limits.

Marc Bovet, Samuel Peters, Thomas Müller-Focke, Patrick Hirschi

Abstract readReview
In one paragraph

Review in Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marc BovetClinical Data Platform for Research, University Hospital Zurich, Zurich, Switzerland, bt.marc@gmail.com.
Samuel PetersDepartment of Radiation Oncology, HOCH Health Ostschweiz, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Thomas Müller-FockeClinical Data Platform for Research, University Hospital Zurich, Zurich, Switzerland.
Patrick HirschiClinical Data Platform for Research, University Hospital Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Background: Business intelligence (BI) solutions are nowadays offered as part of radiation oncology information systems. They support state-of-the-art extraction of structured data for business and research use cases. The variety of use cases often comes with specific customizations for which IT experts are required. Summary: We report about our experience in implementing a BI module in a radiation oncology department, discuss key challenges, and give some recommendations for addressing them. Key Messages: The effectivity of a BI solution strongly interacts with the diverse IT ecosystem of the hospital. It is worth starting with concrete business requirements and involve IT experts from the hospital data warehouse (DWH) or architecture teams. Integration into the enterprise DWH will add value to secondary use of data in the line of good clinical practices. </p>.

Indexed as

Radiation OncologyHumansBusiness intelligenceClinical informaticsData governanceRadiation oncology information systemWorkflow analytics

Identifiers

PMID41348662
PMCPMC12810965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.